Introduction {#S0001}
============

Diabetic patients experience a higher risk of coronary artery disease (CAD) and are more likely to develop more severe symptoms than non-diabetics \[[@CIT0001], [@CIT0002]\]. It is reported that there are more than 220 million people with diabetes worldwide and the number is expected to rise to 360 million by 2030 \[[@CIT0003]\]. About one fifth of patients with unstable angina or non-ST evaluated myocardial infarction have diabetes mellitus, which is associated with advanced CAD, accounting for a higher rate of myocardial infarction and mortality \[[@CIT0004]--[@CIT0006]\]. As the leading cause of mortality among diabetic patients, cardiovascular disease accounts for up to 80% of diabetes-related deaths \[[@CIT0007], [@CIT0008]\].

A clinical trial showed that there was lower mortality and repeat revascularization in diabetic patients treated with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI) \[[@CIT0009]\]. However, drug-eluting stenting (DES) has been recently demonstrated to reduce in-stent restenosis and repeat revascularization compared to bare-metal stenting in diabetic patients. Thus, in the DES era, the optimal revascularization strategy for diabetic patients with multivessel CAD remains unknown \[[@CIT0010]--[@CIT0012]\]. We performed a meta-analysis to compare the efficacy of CABG and DES in diabetic patients with multivessel CAD.

Material and methods {#S0002}
====================

Data sources {#S20003}
------------

We searched Medline, EMBASE, metaRegister of Controlled Trials, and Cochrane databases from January 2003 to July 2013 for clinical studies, using the Medical Subject Heading terms "coronary artery bypass graft surgery", "drug-eluting stent", "diabetes mellitus" and "multivessel coronary artery disease". The Science Citation Index was used to cross-reference studies that met the inclusion criteria.

Study selection {#S20004}
---------------

Studies were selected on the basis of pre-determined criteria: a clinical trial was included if it: (1) was published in journals with the full text in English, (2) compared the use of DES to CABG in diabetic patients with multivessel CAD (≥ 2 arteries), (3) had a follow-up ≥ 12 months. Studies using bare-metal stenting and describing the same article were excluded. The end points were death, myocardial infarction and major adverse cardiac and cerebrovascular events (MACCE). The MACCE was defined as a composite of all-cause death, cerebrovascular accident, myocardial infarction or repeat revascularization (any subsequent PCI or CABG procedure in any coronary vessel).

Data abstraction {#S20005}
----------------

We captured pre-specified data elements for each study, including baseline characteristics and clinic outcomes. Data extraction from text, tables, and figures was performed by 2 independent reviewers. Decisions were compared and a consensus was reached. Discrepancies were resolved through discussion.

Statistical analysis {#S20006}
--------------------

The meta-analysis was conducted with Review Manager 5.2. Forest plots and funnel plots were generated for graphical presentations, and Q statistics were computed to assess heterogeneity across the different studies. We used a fixed-effects model of meta-analysis to aggregate data; however, the randomized-effects model was used when effects were heterogeneous (*I* ^2^ \> 50%). The summary risk differences and odds ratios (OR) comparing CABG and DES outcomes and the 95% CI for each result were computed.

Results {#S0007}
=======

Eligible studies {#S20008}
----------------

Ten studies (2 randomized trials and 8 nonrandomized trials) were included in the meta-analysis and their baseline characteristics are presented in [Table I](#T0001){ref-type="table"} \[[@CIT0012]--[@CIT0021]\]. There was an absence of baseline characteristics of the Banning *et al*. study, because the baseline patient demographics and lesion characteristics in CABG and DES groups were shown as a composite outcome for the diabetic cohort \[[@CIT0018]\]. The rest of the initial citations were excluded based on the titles/abstracts, language, publication type, etc. A total of 5,264 patients were included in the analysis (2,585 CABG and 2,679 DES patients). In most studies, sirolimus-eluting and paclitaxel-eluting stents were provided to the patients in the PCI procedure. However, in the studies of Onuma *et al*. \[[@CIT0014]\] and Yamagata *et al*. \[[@CIT0015]\], PCI was performed by implantation of only sirolimus-eluting stents, whereas only paclitaxel-eluting stents were used in the study of Banning *et al*. \[[@CIT0018]\]. The CABG was performed without elective extracorporeal circulation including a left internal mammary artery for revascularization of the left anterior descending coronary artery whenever possible in most cases. The mean follow-up duration was 3.2 years.

###### 

Baseline characteristics

  Study/year                          Farkouh *et al./* 2012   Domínguez-Franco *et al./*2009   Onuma *et al*./2011                                                      Yamagata *et al*./2010   Tarantini *et al./*2009               Kim *et al*./2012      Briguori *et al*./2007   Qiao *et al./*2009    Lee *et al./*2007
  ----------------------------------- ------------------------ -------------------------------- ------------------------------------------------------------------------ ------------------------ ------------------------------------- ---------------------- ------------------------ --------------------- ------------------------
  **Location**                        Multicenter              Spain                            Multicenter                                                              Japan                    Italy                                 Korea                  Italy                    China                 United States
  **No. of patients**                 953/947                  128/142                          159/96                                                                   92/116                   93/127                                489/402                69/149                   363/282               102/103
  **Design**                          Randomized trial         Retrospective study              Nonrandomized ARTS-II trial compared with the surgical group of ARTS-I   Nonrandomized registry   Prospective, nonrandomized registry   Prospective registry   Nonrandomized registry   Observational study   Nonrandomized registry
  **Follow-up duration \[years\]**    3.8                      2                                5                                                                        3                        2                                     5.6                    1                        1                     1
  **Age**                             63.2/63.1                67.5/65.3                        65/63                                                                    70/67                    65/66.5                               63.5/62.8              63/66                    60.9/62.5             67/68
  **Men**                             698/658                  80/93                            106/66                                                                   66/85                    76/103                                304/275                48/107                   250/221               67/67
  **Stable AP (%)**                   --/--                    --/--                            54/63                                                                    39/59                    75.2/79.5                             --/--                  80/82                    18.2/19.1             42/48
  **Unstable AP (%)**                 --/--                    --/--                            32/33                                                                    22/19                    33.3/19.7                             --/--                  8.5/9.5                  60.3/71.6             41/36
  **Previous MI (%)**                 26.2/25.0                49.2/28.9                        30/49                                                                    57/63                    43.0/55.9                             7.1/27.1               42/37                    20.9/25.2             23/17
  **Hypertension (%)**                --/--                    71.1/59.2                        80/56                                                                    91/92                    90.1/86.6                             64.0/61.4              74/80                    74.1/61.3             89/90
  **Smoking (%)**                     14.8/16.6                39.1/43.7                        12/17                                                                    74/78                    36.5/40.2                             23.1/16.4              30.5/40                  31.6/28.8             16/15
  **Peripheral artery disease (%)**   --/--                    13.3/8.5                         --/--                                                                    22/17                    --/--                                 3.5/10.7               --/--                    --/--                 --/--
  **No. of diseased vessels (%):**                                                                                                                                                                                                                                                                            
  ** 2**                              --/--                    --/--                            49/64                                                                    87/2.6                   54.8/16.5                             52.8/16.4              50.5/13.5                51/18.1               --/--
  ** 3**                              82.3/84.5                57.8/81                          50/35                                                                    13/97                    45.2/83.5                             47.2/83.6              49.5/86.5                49/81.9               --/--
  **Patients with CTO (%)**           --/--                    36.7/47.2                        --/--                                                                    38/44                    5.3/13.4                              5.9/47.0               --/--                    --/--                 9/14
  **SYNTAX score**                    26.2/26.1                18.5/25.9                        --/--                                                                    16/21                    16/21                                 18.3/30.4              18/23                    --/--                 --/--
  **LVEF (%)**                        65.7/66.6                52.4/54.2                        60/60                                                                    47/48                    61.9/62.2                             58.3/54.7              54/53                    59.9/59.5             51/52
  **Insulin-requiring DM (%)**        33.8/30.9                39.8/32.4                        18/17                                                                    13/17                    33.3/28.3                             17.6/18.9              39/36                    15.6/16.9             22/25

Data are expressed as DES/CABG. AP -- angina pectoris, CTO -- chronic total occlusion, LVED -- left ventricle ejection fraction, MI -- myocardial infarction

Study characteristics {#S20009}
---------------------

The CABG group had higher percentages of stable angina pectoris (OR 1.32, 95% CI: 1.06--1.64) ([Figure 1](#F0001){ref-type="fig"}), triple-vessel disease (OR 4.59, 95% CI: 2.08--10.11) ([Figure 2](#F0002){ref-type="fig"}), chronic total occlusion (OR 1.94, 95% CI: 1.29--2.92) ([Figure 3](#F0003){ref-type="fig"}) and SYNTAX scores (mean difference 5.73, 95% CI: 1.67--9.78) ([Figure 4](#F0004){ref-type="fig"}). There is no other significant difference in baseline characteristics between the CABG group and DES group.

![Odds ratio and conclusions plot of stable angina pectoris](AMS-10-23006-g001){#F0001}

![Odds ratio and conclusions plot of triple-vessel disease](AMS-10-23006-g002){#F0002}

![Odds ratio and conclusions plot of chronic total occlusion](AMS-10-23006-g003){#F0003}

![Mean difference and conclusions plot of SYNTAX scores](AMS-10-23006-g004){#F0004}

Clinical outcomes {#S20010}
-----------------

We also performed a subgroup analysis comparing PCI with DES vs. CABG. Among non-randomized studies, OR was comparable between the DES group and the CABG group for the endpoints, with the exception of MACCE rate. There was a significantly higher risk for MACCE in patients treated with DES compared with CABG (OR 0.60, 95% CI: 0.50--0.72). However, DES was associated with significantly increased risks for all three endpoints in the randomized studies. Generally, the OR for mortality was 0.89, indicating that CABG was associated with lower mortality compared with DES, though the effect did not reach statistical significance between the two revascularizations ([Figure 5A](#F0005){ref-type="fig"}). The χ^2^ test with 9 degrees of freedom for the Q statistic was 7.14 (*p* = 0.62, *I* ^2^ = 0%), indicating no significant heterogeneity among the studies. However, there was a statistically significant difference in MACCE rate: CABG could dramatically reduce the rate of MACCE (OR 0.60, 95% CI: 0.52--0.69) ([Figure 6A](#F0006){ref-type="fig"}). There was no significant heterogeneity among the studies as the χ^2^ test with 9 degrees of freedom for the Q statistic was 9.29 (*p* = 0.41, *I* ^2^ = 3%). Additionally, a significant difference in myocardial infarction between the two groups was revealed ([Figure 7A](#F0007){ref-type="fig"}). The OR for myocardial infarction was 0.57 (95% CI: 0.44--0.75), indicating that CABG was associated with lower incidence of myocardial infarction compared with DES. The χ^2^ test with 8 degrees of freedom for the Q statistic was 9.28 (*p* = 0.32, *I* ^2^ =14%), indicating no significant heterogeneity among the studies. In addition, the funnel plot for each endpoint was shown ([Figures 5B](#F0005){ref-type="fig"}, [6B](#F0006){ref-type="fig"} and [7B](#F0007){ref-type="fig"}).

![Forest plot (**A**) and funnel plot (**B**) of mortality](AMS-10-23006-g005){#F0005}

![Forest plot (**A**) and funnel plot (**B**) of MACCE rate](AMS-10-23006-g006){#F0006}

![Forest plot (**A**) and funnel plot (**B**) of myocardial infarction](AMS-10-23006-g007){#F0007}

Discussion {#S0011}
==========

In clinical practice, most patients are treated with PCI for single-vessel disease and with CABG for severe CAD, such as triple-vessel or severe left main disease \[[@CIT0022]\]. Due to the lack of random allocation, patients in observational studies tend to present a large bias. As a result, patients with focal disease are more likely to undergo PCI and those with extensive CAD are likely to undergo CABG. The strategy of revascularization is driven by angiographic data, such as extent, location and nature of the lesion.

A meta-analysis by Lee *et al*. showed that there was no significant difference in death and myocardial infarction between the CABG group and the DES group when the mean follow-up was 18 months (range 12 to 36), which led to the conclusion that PCI with DES was safe and might represent a viable alternative to CABG for patients with diabetes and multivessel CAD \[[@CIT0010]\]. However, in the FREEDOM trial by Farkouh *et al*., 1,900 patients with diabetes and multivessel CAD at 140 centers were enrolled and randomly assigned to undergo either PCI with DES or CABG. The primary outcome measure was a composite of death from any cause, nonfatal myocardial infarction, and nonfatal stroke. They demonstrated that CABG was superior to PCI for diabetic patients with advanced CAD considering the mortality and myocardial infarction \[[@CIT0012]\]. Accordingly, the optimal revascularization strategy for diabetic patients with multivessel CAD remains uncertain.

In our meta-analysis, we conducted a comparison of baseline characteristics between the PCI group and the CABG group. Patients in the CABG group had worse characteristics before being treated, with a higher percentage of stable angina pectoris, triple-vessel disease and chronic total occlusion, and higher SYNTAX scores. Although the mortality was similar in the two groups, the CABG strategy showed superiority for diabetic patients because of the lower rate of myocardial infarction, MACCE and worse baseline characteristics. Therefore, our study, like the FREEDOM trial, further confirmed that CABG had better midterm outcomes than DES.

The major difference between our study and the meta-analysis by Lee *et al*. was the duration of follow-up. The mean follow-up period of the Lee *et al*. meta-analysis was 18 months vs. 3.2 years in ours. Besides, recently published data comparing PCI and CABG were also updated and included in our analysis. In the Lee *et al*. analysis, 5 observational studies (a total of 1543 patients) from January 2003 to July 2009 were included \[[@CIT0014], [@CIT0016], [@CIT0019]--[@CIT0021]\], while five more studies including 3721 participants published recently were included in our meta-analysis \[[@CIT0012], [@CIT0013], [@CIT0015], [@CIT0017], [@CIT0018]\], 2 of which were randomized trials. Moreover, the results of clinical outcomes showed an obvious discrepancy between our analysis and that of Lee *et al*., as noted above.

The 2011 ACCF/AHA guideline showed that CABG (especially with one or both internal mammary arteries) led to more complete revascularization and a decreased need for additional procedures when compared with PCI \[[@CIT0023]\]. Due to the diffuse nature of diabetic CAD, the relative benefits of CABG over PCI may well persist for patients even in the era of DES. The study is not without limitations. First, this meta-analysis adopted the published event rates instead of specific individual data for each trial. Second, there were limited clinical trials included in the analysis and the numbers of patients in each cohort were small. Finally, some results of endpoints were not available, such as data of myocardial infarction in the study by Kim *et al*. \[[@CIT0017]\].

In conclusion, the meta-analysis suggested that the strategy of CABG is better than PCI with DES for diabetic patients with multivessel CAD. In spite of the worse baseline characteristics, the CABG approach could significantly reduce the rate of myocardial infarction and major adverse cardiac cerebrovascular events, while obtaining a similar mortality when compared with PCI.
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